immunotherapy

3:08
Venetoclax-IDH inhibitor combination therapy for AML
Naval Daver
4:09
ADCs for AML: potential alternatives to gemtuzumab ozogamicin
Naval Daver
2:07
ADCs for AML: gemtuzumab ozogamicin
Naval Daver
2:57
Venetoclax and FLT3 inhibitor combination therapy for AML
Naval Daver
1:10
Multiple myeloma treatment: let the war begin!
Gareth Morgan
2:27
CLL: Susan O’Brien’s top ASCO 2019 picks
Susan O’Brien
15:02
The evolving landscape of ALL therapy and the impact of MRD
Dieter Hoelzer et al.
11:42
AML treatment: what does the data say?
Adriano Venditti et al.
2:20
CAR-T assessment in the ambulatory care setting
Diana Comerford
0:47
Patient monitoring following CAR T-cell therapy
Erik Aerts
1:58
Educating and training nurses involved with CAR T-cell therapy
Diana Comerford
1:24
Educational material for HCPs on CAR T-cell therapy
Erik Aertes
1:06
The role of nurses in apheresis during CAR T-cell therapy
Erik Aerts
1:29
Settings for CAR T-cell therapy
Erik Aerts
0:48
HCP collaboration in CAR-T cell therapy
Erik Aerts
1:09
The promise of CAR T-cell therapy in hematological malignancies
Emanuele Ostuni
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals